Chronic kidney disease significantly complicates the emergency management of acute vascular events worldwide. Clinicians often hesitate when selecting reperfusion therapies for patients presenting with both renal dysfunction and acute neurological deficits. However, recent evidence regarding tenecteplase in renal impairment provides critical clarity for acute stroke protocols. This secondary analysis evaluates whether baseline kidney dysfunction alters the clinical benefits and bleeding complications of modern thrombolytic agents. Consequently, emergency teams gain valuable insights into revascularization safety for this vulnerable patient cohort.

Evaluating Tenecteplase in Renal Impairment and Stroke

Acute ischaemic stroke demands rapid clinical decision-making to salvage penumbral brain tissue. Intravenous thrombolysis remains a foundational therapy for eligible patients presenting within four and a half hours of symptom onset. Although alteplase has served as the standard thrombolytic drug for decades, tenecteplase has emerged as an attractive alternative. Tenecteplase offers practical advantages, including rapid single-bolus administration and greater fibrin specificity. Nevertheless, clinicians frequently express concern when administering intravenous thrombolysis to patients with underlying kidney disease. Chronic kidney disease alters drug clearance, impairs vascular integrity, and disturbs baseline coagulation pathways. As a result, these physiological changes elevate the risks of both microvascular thrombosis and fatal hemorrhagic transformation. Historical clinical trials often excluded individuals with advanced renal impairment, leaving a noticeable void in contemporary practice guidelines. Therefore, healthcare providers require robust evidence regarding the comparative safety of these two agents in patients with reduced renal clearance. Understanding these interactions helps physicians optimize thrombolytic choices without causing excessive adverse bleeding events. Furthermore, acute kidney injury often develops concurrently during acute cerebral ischemia. Therefore, emergency clinicians need reliable guidance when evaluating candidates who present with baseline renal disease. Moreover, Indian tertiary centers encounter high proportions of stroke patients with comorbid diabetic nephropathy and chronic hypertension. Thus, establishing the safety profile of newer thrombolytic regimens across renal impairment categories holds immediate clinical relevance for daily emergency practice.

Design and Stratification in the TRACE-2 Analysis

To address these critical knowledge gaps, researchers conducted a post hoc analysis of the landmark TRACE-2 trial. This multicenter randomized controlled study enrolled adults presenting with acute ischaemic stroke within four and a half hours of onset. The investigators specifically evaluated participants who were ineligible for endovascular thrombectomy or could not access mechanical intervention. The trial randomly assigned patients to receive either tenecteplase at 0.25 milligrams per kilogram or alteplase at 0.9 milligrams per kilogram. Furthermore, investigators calculated estimated glomerular filtration rate values using the validated Chronic Kidney Disease Epidemiology Collaboration equation. The team stratified 1,412 participants into three distinct baseline renal categories. The first group comprised patients with normal renal function, defined as an estimated glomerular filtration rate of 90 or higher. Meanwhile, the second group included patients with mildly decreased function, ranging from 60 to 89. Finally, the third group consisted of individuals with moderately to severely decreased kidney function below 60. By examining these three cohorts, the researchers systematically assessed whether renal impairment modified the therapeutic efficacy or safety outcomes of either thrombolytic drug. Additionally, this structured stratification allowed direct comparisons against standard reference cohorts with preserved baseline renal performance.

Comparative Efficacy Across Estimated Glomerular Filtration Rates

The primary efficacy outcome assessed the proportion of patients achieving functional independence at 90 days. Specifically, researchers measured functional recovery through a modified Rankin Scale score between 0 and 1. Patients across all renal function tiers demonstrated comparable functional benefits when receiving tenecteplase versus alteplase. For instance, among individuals with normal renal function, 65.5 percent of tenecteplase recipients achieved functional independence compared to 61.2 percent in the alteplase arm. Similarly, patients with mildly impaired renal clearance demonstrated favorable response rates between the two therapeutic cohorts. In the moderate-to-severe renal dysfunction subgroup, 46.7 percent of tenecteplase patients attained functional recovery versus 52.0 percent of alteplase patients. Importantly, formal statistical testing confirmed no significant interaction between baseline kidney dysfunction and treatment assignment. Renal impairment indeed predicted lower absolute recovery rates across both therapeutic groups. However, the presence of kidney disease did not diminish the relative therapeutic effectiveness of tenecteplase compared with alteplase. Consequently, clinicians can anticipate consistent thrombolytic efficacy from tenecteplase regardless of baseline glomerular filtration rates. Furthermore, secondary analyses demonstrated consistent functional independence across varying degrees of neurological impairment. Thus, tenecteplase maintains dependable therapeutic reperfusion regardless of glomerular filtration rates. Therefore, these findings reassure clinicians that renal dysfunction does not impair the therapeutic reperfusion benefit offered by modern thrombolytic agents.

Safety Profiles and Intracranial Hemorrhage Risks

Evaluating safety endpoints represents a paramount objective when treating patients with acute stroke and compromised kidney function. In this analysis, the primary safety endpoint focused on symptomatic intracranial hemorrhage occurring within 36 hours. Notably, tenecteplase did not increase the risk of symptomatic intracranial bleeding in patients with impaired renal function compared to normal controls. However, renal impairment significantly increased the odds of 90-day all-cause mortality among tenecteplase recipients. Patients with mild renal decline exhibited higher mortality, and those with moderate-to-severe disease showed a marked increase in fatal events. In contrast, patients receiving alteplase experienced both elevated mortality and a tenfold increase in symptomatic intracranial hemorrhage when presenting with moderate-to-severe renal failure. Statistical interaction analyses showed no significant overall difference between tenecteplase and alteplase for hemorrhagic transformations. Furthermore, rates of major systemic bleeding remained similar across both treatment arms regardless of baseline kidney performance. Consequently, the observed increase in overall mortality reflects systemic cardiovascular frailty and chronic vascular disease rather than direct drug toxicity. Physicians must therefore recognize that systemic multimorbidity drives long-term mortality in this patient population. Importantly, these safety outcomes highlight that clinicians should not deny thrombolysis to patients solely because of renal impairment. However, intensive neurological and physiological monitoring remains essential during the post-thrombolytic period.

Clinical Implications for Emergency and Stroke Practice

These findings carry profound clinical implications for emergency departments and acute stroke networks, particularly in resource-constrained environments. Clinicians should never withhold or delay intravenous thrombolytic therapy simply because a patient presents with baseline renal disease. Tenecteplase offers equal clinical efficacy to alteplase without augmenting intracranial hemorrhagic risks in renal failure. Moreover, tenecteplase provides distinct operational advantages through rapid single-bolus intravenous delivery. A single bolus eliminates the need for one-hour intravenous infusions, thereby streamlining emergency workflows and facilitating faster secondary transfers. In Indian hospitals, where inter-facility transport times can introduce significant treatment delays, single-bolus administration preserves vital time. Additionally, healthcare providers must establish rigorous post-thrombolysis monitoring protocols to manage systemic cardiovascular risks in patients with chronic kidney disease. Clinicians should actively address blood pressure fluctuations, metabolic disturbances, and secondary vascular complications during acute hospitalization. Ultimately, tenecteplase serves as an efficient, safe, and pragmatic alternative to alteplase for stroke patients with varying degrees of renal impairment. Furthermore, interdisciplinary collaboration between neurologists, nephrologists, and critical care teams optimizes long-term survival for these medically complex patients. By adopting tenecteplase protocols, healthcare institutions can simplify acute stroke care while maintaining robust patient safety standards.

Does renal impairment increase the risk of intracranial hemorrhage after tenecteplase?

In the TRACE-2 analysis, renal impairment did not increase the incidence of symptomatic intracranial hemorrhage in patients treated with tenecteplase compared to normal kidney function. However, alteplase was associated with higher hemorrhagic risks in severe renal impairment. Tenecteplase demonstrated a favorable safety profile regarding intracranial bleeding across all renal categories.

Should physicians adjust the tenecteplase dosage for patients with chronic kidney disease?

Current stroke guidelines and the TRACE-2 protocol recommend standard weight-based dosing of 0.25 milligrams per kilogram up to 25 milligrams without dose reduction for renal failure. Tenecteplase undergoes hepatic clearance rather than primary renal excretion. Therefore, dose reductions are unnecessary and may compromise arterial recanalization and functional neurological recovery.

Why do stroke patients with renal impairment experience higher 90-day mortality?

Higher 90-day mortality in patients with impaired renal function stems primarily from advanced systemic cardiovascular disease, severe endothelial dysfunction, and multimorbidity rather than direct thrombolytic toxicity. Both tenecteplase and alteplase cohorts exhibited elevated mortality in reduced kidney function, emphasizing the necessity of comprehensive, long-term post-stroke cardiovascular and metabolic management.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional for diagnosis and treatment decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Wu Y et al. Influence of impaired renal function on the outcomes of patients with acute ischaemic stroke treated with intravenous tenecteplase and alteplase: a post hoc analysis of the TRACE-2 trial. Stroke Vasc Neurol. 2025 Oct 27. doi: 10.1136/svn-2024-003726. PMID: 40102020.
2. Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet. 2023;401(10377):645-654.
3. Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161-169.